BE0003755692 - Common Stock

Taking everything into account, **AGFB** scores **2** out of 10 in our fundamental rating. **AGFB** was compared to 13 industry peers in the **Health Care Technology** industry. While **AGFB** seems to be doing ok healthwise, there are quite some concerns on its profitability. **AGFB** is valued expensive and it does not seem to be growing.

In the past 5 years **AGFB** reported 4 times negative operating cash flow.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -4.01% | ||

ROE | -14.47% | ||

ROIC | N/A |

ROA(3y)-6.95%

ROA(5y)0.93%

ROE(3y)-23.67%

ROE(5y)-5.43%

ROIC(3y)N/A

ROIC(5y)N/A

In the last couple of years the **Operating Margin** of **AGFB** has declined.

Looking at the **Gross Margin**, with a value of **30.71%**, **AGFB** is doing worse than **75.00%** of the companies in the same industry.

In the last couple of years the **Gross Margin** of **AGFB** has remained more or less at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 30.71% |

OM growth 3Y-17.71%

OM growth 5Y-24.95%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y2.5%

GM growth 5Y-0.57%

The number of shares outstanding for **AGFB** has been reduced compared to 5 years ago.

Compared to 1 year ago, **AGFB** has a worse debt to assets ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.21 | ||

Debt/FCF | N/A | ||

Altman-Z | 2.18 |

ROIC/WACCN/A

WACC9.25%

A Quick Ratio of **1.15** indicates that **AGFB** should not have too much problems paying its short term obligations.

Looking at the **Quick ratio**, with a value of **1.15**, **AGFB** is in line with its industry, outperforming **50.00%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.96 | ||

Quick Ratio | 1.15 |

The **Earnings Per Share** has grown by an impressive **79.20%** over the past year.

The Revenue for **AGFB** has decreased by **-33.65%** in the past year. This is quite bad

EPS 1Y (TTM)79.2%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%67.44%

Revenue 1Y (TTM)-33.65%

Revenue growth 3Y-12.37%

Revenue growth 5Y-12.1%

Sales Q2Q%-7.41%

Based on estimates for the next years, **AGFB** will show a very strong growth in **Earnings Per Share**. The EPS will grow by **31.13%** on average per year.

EPS Next Y74.5%

EPS Next 2Y42.96%

EPS Next 3Y31.13%

EPS Next 5YN/A

Revenue Next Year-1.04%

Revenue Next 2Y1.07%

Revenue Next 3Y2.03%

Revenue Next 5YN/A

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

The **Price/Earnings Ratio** is negative for **AGFB**. In the last year negative earnings were reported.

When comparing the **Price/Forward Earnings** ratio of **AGFB** to the average of the S&P500 Index (**19.80**), we can say **AGFB** is valued expensively.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 57.75 |

Compared to the rest of the industry, the **Enterprise Value to EBITDA** ratio of **AGFB** indicates a rather cheap valuation: **AGFB** is cheaper than 83.33% of the companies listed in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | 6.88 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y42.96%

EPS Next 3Y31.13%

No dividends for **AGFB**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**AGFA-GEVAERT NV**

EBR:AGFB (5/30/2024, 4:55:44 PM)

**1.178**

**+0.02 (+1.9%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Technology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap182.38M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 57.75 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -4.01% | ||

ROE | -14.47% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 30.71% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.82

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.21 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.96 | ||

Quick Ratio | 1.15 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)79.2%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y74.5%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-33.65%

Revenue growth 3Y-12.37%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y